STAT3 Overview
Molecule Name
Signal transducer and activator of transcription 3
Synonyms
STAT3, signal transducer and activator of transcription 3
Drug Development Progress
Drugs in Clinical Trials21
Approved Drugs4
Highest Development StageApproved
Target Synonym
Acute-phase response factor，APRF，STAT3，Signal Transducer And Activator Of Transcription 3 (Acute-Phase Response Factor)，Signal transducer and activator of transcription 3，DNA-Binding Protein APRF，ADMIO1，ADMIO，HIES，STAT3 Transcription Factor
Background
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes important for essential cellular processes including survival, proliferation, self-renewal, angiogenesis, and immune response. As an early tumor diagnostic marker, it is considered that constitutive STAT3 activation is a sufficient factor to cause malignant transformation and tumor development in model systems. The classical IL-6/STAT3 signaling pathway in cancer cells. IL-6 binds to the membrane-bound IL-6 receptor α (IL-6R) and IL-6 receptor β (also known as gp130). The IL-6/IL-6R/gp130 complex activate the phosphorylation of JAKs, followed by STAT3 phosphorylation and activation. Then, phosphorylated STAT3 forms a homodimer and translocates into the nucleus to bind to the promotor region of target genes and activates target gene transcription.
STAT3 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Napabucasin | DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) | Phase 3 Clinical | 1globe Biomedical Co Ltd, Boston Biomedical Inc, Pharmaceutics International Inc | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Hematologic Neoplasms; Mesothelioma; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Isoquercetin | IQC-950AN; ISQ950AN | Phase 3 Clinical | Quercegen Pharmaceuticals | Anemia, Sickle Cell; beta-Thalassemia; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Coronavirus Disease 2019 (COVID-19); Diabetic Nephropathies; Kidney Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Renal Insufficiency, Chronic; Venous Thromboembolism | Details |
| Dimethylaminomicheliolide Fumarate | ACT-001 | Phase 3 Clinical | Tianjin Accendatech Technology Co Ltd | Brain metastases; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Glioma; Melanoma; Neuromyelitis Optica; Optic Neuritis; Small Cell Lung Carcinoma; Solid tumours | Details |
| Nanocurcumin (Tehran University of Medical Sciences) | Phase 2 Clinical | Tehran University Of Medical Sciences | Neoplasms; Periapical Diseases | Details | |
| Danvatirsen | AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Ascites; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mismatch Repair Deficient Cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| M-1001 | M-1001; MEDICA-M1001 | Phase 2 Clinical | Syndromex | Dyslipidemias | Details |
| Ivarmacitinib sulfate Base gel(Jiangsu Hengrui Medicine) | SHR0302 base | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Vitiligo | Details |
| NT-219 | NT-219; NT219 | Phase 2 Clinical | TyrNovo Ltd | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| C-188-9 | C188-9; C-188-9; TTI-101 | Phase 2 Clinical | Baylor College Of Medicine | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Idiopathic Pulmonary Fibrosis; Melanoma; Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| WP-1066 | WP-1066 | Phase 2 Clinical | Moleculin Biotech Inc | Brain metastases; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioblastoma; Glioma; Medulloblastoma; Melanoma | Details |
| OPB-111077 | OPB-111077; OPC-317 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Neoplasms; Solid tumours | Details |
| YY-201 | YY-201; YY201 | Phase 1 Clinical | Shanghai Yuyao Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Extranodal NK-T-Cell; Pancreatic Neoplasms; Solid tumours | Details |
| GLG-302 | GLG-302; GLG-805; S31-201; NSC-74859 | Phase 1 Clinical | H Lee Moffitt Cancer Center & Research Institute | Breast Neoplasms | Details |
| Amcasertib/Napabucasin | Phase 1 Clinical | Boston Biomedical Inc | Neoplasms | Details | |
| JW-2286 | ST-2286; JW2286; JW-2286 | Phase 1 Clinical | C&C Research Laboratories | Breast Neoplasms; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Lirodegimod | KT-333; I-003 | Phase 1 Clinical | Kymera Therapeutics Inc | Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Solid tumours | Details |
| NN-4002 | NN4002; NN-4002 | Phase 1 Clinical | Novo Nordisk A/S | Lymphoma, Non-Hodgkin; Solid tumours | Details |
| VVD-130850 | VVD-130850; BAY-3630914; VVD-850 | Phase 1 Clinical | Vividion Therapeutics Inc | Hematologic Neoplasms; Solid tumours | Details |
| DCR-STAT3 | DCR-STAT3 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Neoplasms; Solid tumours | Details |
| OPB-171775 | OPB-171775 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| STAT3 decoys (University of Pittsburgh/University of Pittsburgh-Office of Technology Management) | Clinical | University Of Pittsburgh | Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Golotimod | SCV-07 | Approved | Verta | Russian Federation | Mucositis; Hepatitis C | null | 2009-01-01 | Head and Neck Neoplasms; Hepatitis C; Mucositis; Stomatitis | Details | |
| Ivarmacitinib sulfate | SHR-0302; ARQ-252; ARQ-255 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾速达 | Mainland China | Spondylitis, Ankylosing | Jiangsu Hengrui Medicine Co Ltd | 2025-03-18 | Alopecia Areata; Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Eczema; Graft vs Host Disease; Hepatic Insufficiency; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Peripheral; Metastatic breast cancer; Non-radiographic axial spondyloarthritis; Sedation; Solid tumours; Spondylarthritis; Spondylitis, Ankylosing; Triple Negative Breast Neoplasms; Vitiligo | Details |
| Nifuroxazide | Approved | Ambatrol | Colitis; Diarrhea | Details | ||||||
| Caffeic Acid | CABE | Approved | Moleculin Llc, The University Of Texas MD Anderson Cancer Center | Hemorrhage; Leukopenia; Thrombocytopenia | Details |